Sunshine Biopharma Announces Issuance of Notice of Allowance for the Patent Application Covering its Adva-27a Anti-Cancer Compound
MONTREAL, Apr 09, 2012 (BUSINESS WIRE) -- Sunshine Biopharma Inc. (OTCBB: SBFM) is pleased to announce that it has recently received notification that the United States Patent and Trademark Office has issued a "Notice of Allowance" for the patent application covering its lead anti-tumor compound, Adva-27a. The allowed claims protect Adva-27a and extensively cover various formulations, derivatives and cancer applications. Sunshine Biopharma's recently announced preclinical results showed that Adva-27a has an excellent pharmacokinetics profile in rats and remarkable cytotoxic activity against a variety of cancer cells, particularly multidrug resistant Breast Cancer cells. Adva-27a is appears to be unique in its ability to destroy multidrug resistant cancer cells. Sunshine Biopharma is moving forward with the next steps in the development of Adva-27a which include GMP manufacturing, IND-enabling studies and Phase I clinical trials.

Safe Harbor Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

SOURCE: Sunshine Biopharma Inc.

 CONTACT:           
 
 

Sunshine Biopharma Inc. Mr. Camille Sebaaly Tel: 514-764-9698 Fax: 514-764-9699 Direct: 514-814-0464 info@sunshinebiopharma.com www.sunshinebiopharma.com

 Copyright Business Wire 2012 
 
 

-0-